Robins Chad M
SEC Form 4 history across 1 companies, 8 transactions and 1 filings.
Available history · Aug 17, 2026 – Aug 18, 2026
Latest insider transactions
Form 4 filings from available history.| Company | Insider | Activity | Disclosed value | Filed (ET) |
|---|---|---|---|---|
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | M · exerciseDerivative securitySEC filing ↗ | $0View disclosure → | |
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | S · saleSEC filing ↗ | -$5.12kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | S · saleSEC filing ↗ | -$6.81MView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | M · exerciseSEC filing ↗ | $1.82MView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | S · saleSEC filing ↗ | -$64.5kView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | S · saleSEC filing ↗ | -$7.99MView disclosure → | |
ADPTAdaptive Biotechnologies Corp | Robins Chad MCHAIR | M · exerciseSEC filing ↗ | $2.10MView disclosure → |
Latest Form 4 facts
Quick context from source filings
sale at Adaptive Biotechnologies Corp on Aug 18, 2026 valued at $5,129.
Review SEC filingNo open-market insider purchase is available.
Monthly open-market activity
Last 1 reported months · purchases and sales
View exact monthly values
| Month | Purchases | Sales | Buy value | Sale value | Net value |
|---|---|---|---|---|---|
| Aug 2026 | 0 | 4 | $0.00 | $14,882,166.29 | -$14,882,166.29 |
Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.
Ownership and transaction size
Ownership and ticket size
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Companies in the disclosed reporting history
Open-market buy performance
90-day forward return on this insider's open-market purchases
A 90-day purchase return requires an open-market buy. No eligible purchases are recorded in this history.
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
6 observations · Aug 17, 2026 – Aug 18, 2026. Window ends at the latest available report, not today.
View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Aug 17, 2026 | 2,501,842 | Aug 20, 2026 | View transaction |
| Aug 17, 2026 | 2,183,043 | Aug 20, 2026 | View transaction |
| Aug 17, 2026 | 2,180,518 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 2,459,194 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 2,180,722 | Aug 20, 2026 | View transaction |
| Aug 18, 2026 | 2,180,518 | Aug 20, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Robins Chad M Insider Activity FAQ
SEC Form 4 context
Who is Robins Chad M?
Robins Chad M is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001780649.
Which companies has Robins Chad M reported transactions for?
Adaptive Biotechnologies Corp
When was Robins Chad M's latest insider buy?
No open-market insider purchase is available for this period.
When was Robins Chad M's latest insider sale?
sale at Adaptive Biotechnologies Corp on Aug 18, 2026 valued at $5,129.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.